Eurofins-Cerep SA
ALECR
Company Profile
Business description
Eurofins-Cerep SA provides in vitro pharmacology, in vitro ADME-Tox and in vivo PK services and solutions. The company also offers cost-effective drug discovery by identifying at early stages drug candidates and eliminating them. Some solutions provided by the company are - compound management, high-throughout screening, in vitro safety profiling, lead optimization profiling, in vitro ADME profiling, and in vivo PK.
Contact
Le bois l Eveque
Celle l Evescault86600
FRAT: +33 549893000
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
197
Stocks News & Analysis
stocks
Wide moat stock exchange remains cheap
Aussie stock exchange remains materially undervalued despite growing cost concerns.
stocks
ASX data center player expands pipeline but questions remain
Questions surround Australia’s largest data center developer and its growing pipeline.
stocks
Cheap e-commerce share continues sales momentum
The e-commerce business continues its sales momentum despite challenging backdrop.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,965.00 | 77.80 | 0.88% |
| CAC 40 | 8,183.34 | 5.53 | -0.07% |
| DAX 40 | 25,104.70 | 12.45 | 0.05% |
| Dow JONES (US) | 51,032.46 | 363.49 | 0.72% |
| FTSE 100 | 10,409.28 | 16.68 | -0.16% |
| HKSE | 25,182.39 | 176.23 | 0.70% |
| NASDAQ | 26,972.62 | 55.15 | 0.20% |
| Nikkei 225 | 66,329.50 | 1,636.38 | 2.53% |
| NZX 50 Index | 13,244.55 | 38.44 | 0.29% |
| S&P 500 | 7,580.06 | 16.43 | 0.22% |
| S&P/ASX 200 | 8,731.70 | 73.10 | 0.84% |
| SSE Composite Index | 4,068.57 | 30.07 | -0.73% |